Blueprint Medicines Corp

NASDAQ:BPMC  
96.41
+3.61 (+3.89%)
Products

FDA Approves Blueprint Medicines' Gavreto (Pralsetinib) Capsules, For Oral Use

Published: 12/01/2020 19:47 GMT
Blueprint Medicines Corp (BPMC) - FDA Approves Blueprint Medicines' Gavreto (pralsetinib) Capsules, for Oral Use.
FDA Says Approves Gavreto for Treatment of Adult Patients With Metastatic Rearranged During Transfection Fusion-positive Non-small Cell Lung Cancer.
FDA Says Approves Gavreto for Treatment of Adult,pediatric Patients With Advanced/metastatic Ret-mutant Mtc Requiring Systemic Therapy.
FDA - Approves Gavreto for Treatment of Adult,pediatric Patients With Advanced/metastatic Ret Fusion-positive Thyroid Cancer.